Maarten van der Doelen

Patient-reported outcomes in mCRPC patients treated with radium-223 therapy

Table 2B. Baseline patient-reported outcomes on psychological distress and fatigue.

Subgroup 1-3 injections (N=19) Mean (SD)

Subgroup 4-5 injections (N=18) Mean (SD)

Subgroup 6 injections (N=59) Mean (SD)

Total cohort (N=96) Mean (SD)

HADS a

Anxiety score

5.5 (4.0)

6.0 (4.2)

6.2 (3.2)

5.2 (4.1)

Depression score

5.5 (4.3)

7.1 (5.7)

5.9 (3.9)

4.8 (3.7)

Total score

11.0 (7.8)

13.1 (9.4)

12.1 (6.5)

10.0 (7.5)

CIS Fatigue a

Fatigue severity subscale

33.5 (13.6)

33.5 (16.0)

36.0 (11.5)

32.7 (13.5)

a High scores indicate high symptom burden.

4

Global health status

Physical functioning

Role functioning

100

100

100

1-3

6 injections

1-3

6 injections

1-3

6 injections

4-5

4-5

4-5

80

80

80

60

60

60

40 Mean score

40 Mean score

40 Mean score

20

20

20

T0

T1

T2

T0

T1

T2

T0

T1

T2

Time point

Time point

Time point

Emotional functioning

Cognitive functioning

Social functioning

100

100

100

1-3

6 injections

1-3

6 injections

1-3

6 injections

4-5

4-5

4-5

80

80

80

60

60

60

40 Mean score

40 Mean score

40 Mean score

20

20

20

T0

T1

T2

T0

T1

T2

T0

T1

T2

Time point

Time point

Time point

Figure 2. Course of cancer-specific health-related quality of life (EORTC QLQ-C30 functional scales and global health status) over time in patients treated with radium-223 for metastatic castration-resistant prostate cancer. Bars indicate mean scores with 95% confidence intervals.

99